CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2018--
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company
focused on developing compounds that activate Tie2 to treat ocular
diseases and diabetic complications, today announced that Chief
Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the
Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at
8:00 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a
corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class compounds that activate Tie2 to treat ocular
diseases and complications of diabetes. Tie2 is an important regulator
of vascular stability and its down-regulation is found in patients with
diabetes. Down-regulation is caused by activation of two inhibitors of
Tie2, VE-PTP and Ang-2 due to hypoxia or tissue ischemia. The Company’s
lead compound, AKB-9778, is a systemically-administered small molecule
activator of the Tie2 pathway (via highly selective and potent
deactivation of VE-PTP) and is in clinical development for the treatment
of non-proliferative diabetic retinopathy. AKB-9778 is also being
investigated for its potential utility in treating diabetic nephropathy
and an eyedrop formulation is in development as a potential treatment
for open-angle glaucoma. For more information, please visit www.aerpio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181108005011/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor & Media:
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.
Steinberg / Robert Flamm, Ph.D.